NT Pharma Announces Executive Shift in Secretarial and Compliance Roles

Stock News

1 hour ago

NT Pharma (01011) has officially announced leadership changes within its administrative and compliance framework, which took effect on August 31, 2026.

According to the company's latest filing, Ms. Li Yifang has stepped down from her positions as Company Secretary, Authorized Representative under Rule 3.05 of the Hong Kong Stock Exchange Listing Rules, and Process Agent for legal service in Hong Kong as per Rule 19.05(2) and Part 16 of the Companies Ordinance (Chapter 622).

In a corresponding appointment, Mr. Wang Zhiqiang has assumed these roles, becoming the new Company Secretary, Authorized Representative, and Process Agent, effective from the same date. This transition marks a strategic move in the company's ongoing corporate governance adjustments.

The board expressed confidence in Mr. Wang's capabilities to uphold the regulatory compliance and procedural integrity required for these critical functions. These changes align with the company’s commitment to maintaining robust corporate standards and seamless administrative operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1194834973"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194834973\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194834973?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194834973","market":"sg","top_or_hot":-1,"title":"NT Pharma Announces Executive Shift in Secretarial and Compliance Roles","media":"Stock News","content":"<p>NT Pharma (01011) has officially announced leadership changes within its administrative and compliance framework, which took effect on August 31, 2026.<br><br>According to the company's latest filing, Ms. Li Yifang has stepped down from her positions as Company Secretary, Authorized Representative under Rule 3.05 of the Hong Kong Stock Exchange Listing Rules, and Process Agent for legal service in Hong Kong as per Rule 19.05(2) and Part 16 of the Companies Ordinance (Chapter 622).<br><br>In a corresponding appointment, Mr. Wang Zhiqiang has assumed these roles, becoming the new Company Secretary, Authorized Representative, and Process Agent, effective from the same date. This transition marks a strategic move in the company's ongoing corporate governance adjustments.<br><br>The board expressed confidence in Mr. Wang's capabilities to uphold the regulatory compliance and procedural integrity required for these critical functions. These changes align with the company’s commitment to maintaining robust corporate standards and seamless administrative operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT Pharma Announces Executive Shift in Secretarial and Compliance Roles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT Pharma Announces Executive Shift in Secretarial and Compliance Roles\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-31 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NT Pharma (01011) has officially announced leadership changes within its administrative and compliance framework, which took effect on August 31, 2026.<br><br>According to the company's latest filing, Ms. Li Yifang has stepped down from her positions as Company Secretary, Authorized Representative under Rule 3.05 of the Hong Kong Stock Exchange Listing Rules, and Process Agent for legal service in Hong Kong as per Rule 19.05(2) and Part 16 of the Companies Ordinance (Chapter 622).<br><br>In a corresponding appointment, Mr. Wang Zhiqiang has assumed these roles, becoming the new Company Secretary, Authorized Representative, and Process Agent, effective from the same date. This transition marks a strategic move in the company's ongoing corporate governance adjustments.<br><br>The board expressed confidence in Mr. Wang's capabilities to uphold the regulatory compliance and procedural integrity required for these critical functions. These changes align with the company’s commitment to maintaining robust corporate standards and seamless administrative operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01011","symbol_name":"泰凌医药","start_time":0,"source_url":"","article_id":"1194834973","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194834973","pubTimestamp":1788182895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"NT Pharma (01011) has officially announced leadership changes within its administrative and compliance framework, which took effect on August 31, 2026.According to the company's latest filing, Ms. Li...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01011":"泰凌医药","BK1191":"制药"},"translate_title":"NT Pharma 宣布秘书和合规职位的高管变动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"NT Pharma (01011) has officially announced leadership changes within its administrative and compliance framework, which took effect on August 31, 2026.According to the company's latest filing, Ms. Li Yifang has stepped down from her positions as Company Secretary, Authorized Representative under Rule 3.05 of the Hong Kong Stock Exchange Listing Rules, and Process Agent for legal service in Hong Kong as per Rule 19.05(2) and Part 16 of the Companies Ordinance (Chapter 622).In a corresponding appointment, Mr. Wang Zhiqiang has assumed these roles, becoming the new Company Secretary, Authorized Representative, and Process Agent, effective from the same date. This transition marks a strategic move in the company's ongoing corporate governance adjustments.The board expressed confidence in Mr. Wang's capabilities to uphold the regulatory compliance and procedural integrity required for these critical functions. These changes align with the company’s commitment to maintaining robust corporate standards and seamless administrative operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}